Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hospira Hinges Emerging Market Success On Scale And Differentiation

This article was originally published in PharmAsia News

Executive Summary

Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan

You may also be interested in...



Emerging Views On Emerging Markets: Sanford C. Bernstein & Co. Strategic Decisions Conference

PharmAsia News takes a closer look at presentations by BMS, Celgene, Lilly and Hospira.

A Closer Look At China’s 2012 Essential Drug Expansion

China is likely to focus on drugs with large consumption patterns for the revised EDL, including anti-hypertensive drugs and oncology drugs.

A Closer Look At China’s 2012 Essential Drug Expansion

China is likely to focus on drugs with large consumption patterns for the revised EDL, including anti-hypertensive drugs and oncology drugs.

Related Content

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel